top of page
Predictable, Precise, Practical MedTour
Search


CAR‑T Q&A Part: Known as the “Anti‑Cancer Special Forces” — Who Is Eligible and Is It Worth Trying?
CAR‑T is no universal miracle drug. It has well‑defined eligibility criteria, standardised workflows and controllable risks. Nor is it always a patient’s final therapeutic option; for many high‑risk haematology patients, it may represent the first step toward cure.
Anxious patients are advised not to draw premature conclusions or give up hope. Bring your complete medical records for comprehensive assessment by an experienced CAR‑T team to identify the most suitable treatment
Elva Chen
Nov 24 min read


Stem‑Cell Transplant Q&A: Do I Really Need a Transplant? — A Decision‑Making Guide for Various Hematological Diseases
CAR‑T addresses how to eliminate existing tumors; transplantation addresses how to prevent tumor recurrence. Each modality bears unique strengths. Treatment selection depends on disease subtype, risk stratification, treatment response and physical condition, and requires thorough discussion with attending clinicians.
Elva Chen
Oct 304 min read


CAR‑T Q&A | Who Is Eligible for CAR‑T Therapy? What Pre‑Treatment Preparations Are Required?
Seven CAR‑T products have gained regulatory approval in China, predominantly targeting CD19 (for B‑cell leukaemia and lymphoma) and BCMA (for multiple myeloma). Each product has distinct indications. At experienced centres such as Beijing Boren Hospital, clinicians select optimal CAR‑T products tailored to each patient’s disease profile, subtype and target antigen expression.
Elva Chen
Oct 264 min read


Chinese American Travels Across Oceans for Treatment: Groundbreaking CAR-T Therapy Saves His Life
A Chinese American crossed oceans to receive life-saving treatment for gastric cancer at Sir Run Run Shaw Hospital. Having failed multiple therapies in the US, he was treated with CT041, the world’s first approved CAR-T therapy for solid tumors. Led by Dr. Zheng Yu’s team. The patient tolerated treatment well; his wound healed and condition improved. Targeting CLDN18.2, CT041 cuts progression or death risk by 63% for heavily pre-treated gastric cancer patients.
Elva Chen
Oct 203 min read


1st International Oncology Treatment Forum Held in Foshan: Fosun Health Builds an International Academic Exchange Platform for Oncology
The 1st International Oncology Treatment Forum was held in Foshan by Fosun Health, gathering 200+ oncology experts from 15 nations. The Global Oncology Collaboration Alliance was launched to build cross‑border tele‑consultation and second‑opinion networks. Sessions covered precision radiotherapy, CyberKnife, BNCT, CAR‑T and TCM‑integrated oncology. Fosun Health also unveiled its end‑to‑end navigation model for overseas cancer patients, advancing patient‑centred global medical
Elva Chen
Sep 215 min read


First‑ever Foreign Patient Treated with Solid‑Tumor CAR‑T Therapy Discharged from Jiahui International Cancer Center
“Before settling on Jiahui, I received treatment proposals from hospitals in Saudi Arabia and the United States. I chose Jiahui for their prompt replies and efficient communication. This innovative solid‑tumor CAR‑T therapy was also the most accessible option for my condition,” Josh recalled. “I had never visited China before, so I was anxious. Fortunately, I met the Jiahui team, especially Dr. Xuan, who practiced medicine in the United States for two decades.
Elva Chen
Aug 213 min read


Breakthrough for the World’s First Solid Tumor CAR-T: First International Patient Completes Apheresis at Jiahui International Cancer Center
Shanghai, July 6, 2026 — Jiahui International Cancer Center (JICC) announced that a 59-year-old male patient from New Zealand has successfully finished T-cell apheresis for Satricabtagene autoleucel (CT041). This marks the first international patient to complete T-cell collection in China for the world’s first approved solid tumor CAR-T therapy, demonstrating China’s global competitiveness in translational cell therapy and showcasing Chinese innovative treatments to global pa
Elva Chen
Aug 42 min read


Beijing GoBroad Boren Hospital| Expert Perspective | Director Hu Kai: What You Need to Know About CAR-T Therapy for Malignant Lymphoma & Multiple Myeloma
The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.
Elva Chen
Jul 283 min read


Notes on Genetic Diagnosis
Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target
Elva Chen
Jul 262 min read


Director Zheng Qinlong: Why Genetic Testing Is Growing Critical in Leukemia Diagnosis & Treatment
Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.
Elva Chen
Jul 164 min read


Beijing Gobroad Boren Hospital: How Can CAR-T Cells Win the Long-Term Battle? Long-Term Efficacy Depends on More Than a Single Infusion
Many patients wonder: How long can CAR-T therapy last? Its long-term efficacy depends not only on the initial anti-tumor effect but also on the persistence of CAR-T cells in the body. Factors like T-cell quality, production process, tumor immune escape, and standardized whole-process management all affect outcomes. To improve durability, doctors recommend early intervention, optimized cell preparation, personalized targets, and long-term monitoring.
Elva Chen
Jul 94 min read


First Foreign Patient Treated with Axicabtagene Ciloleucel CAR-T Therapy Discharged from Shanghai Jiahui International Hospital
China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.
Elva Chen
Jun 285 min read


The World’s First CAR-T Cell Therapy for Solid Tumors – Kailimei® (Sorrentide Autologous Cell Injection, CT041) Approved for Marketing
The world’s first CAR-T therapy for solid tumors, Kailimei® (CT041), has been approved in China for advanced gastric cancer. A milestone breakthrough, it marks China’s leap from follower to leader in solid tumor cell therapy. Jiahui International Cancer Center is among the first to offer this innovative treatment, bringing new hope to patients.
Elva Chen
Jun 262 min read


Industry Report! NK Cell Therapy: The Potential Dark Horse in the Next 100-Billion-Yuan Market
Unlike CAR-T therapy which is mainly concentrated in hematologic malignancies, NK cell therapy has broader application scenarios. It not only shows good prospects in the treatment of solid tumors such as lung cancer, liver cancer and colorectal cancer, but also has potential value in autoimmune diseases, neurological diseases and other fields, making up for the shortcomings of existing treatment methods.
Elva Chen
Mar 274 min read


Delegation from Bangkok Hospital Visits Jiahui Health for In-Depth Exchanges on Oncology Diagnosis, Treatment and Innovation
Recently, a delegation from Bangkok Hospital visited Jiahui Health, and the two sides held exchanges focusing on oncology diagnosis, treatment and innovation. The two sides focused on cutting-edge topics in clinical oncology – ranging from surgical operations to advanced and sophisticated therapies such as CAR-T, as well as the application practice of new anti-tumor drugs in China.
Elva Chen
Mar 221 min read


CAR-T Cell Therapy
The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].
Elva Chen
Mar 182 min read


Guidelines | Guidelines for the Clinical Application of Malignant Tumor Immunotherapy Technologies (Abridged Version)
Malignant tumors are one of the major diseases seriously threatening human health and life, Based on existing evidence-based medical evidence, combined with domestic and international guidelines and consensuses, the Chinese Anti-Cancer Association (CACA) has formulated these Guidelines for the Clinical Application of Malignant Tumor Immunotherapy Technologies, aiming to provide assistance to clinicians engaged in clinical immunotherapy.
Elva Chen
Dec 23, 202518 min read


Unveiling BCMA/CD19 CAR-T Therapy: Why ORR Reaches 100% in NDMM
At the 2025 American Society of Hematology (ASH) Annual Meeting, Senior journalist Peter Goodwin from Audio Journal of Oncology invited Professor Du Juan from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an on-site interview regarding her team’s research: "FasTCAR-T (GC012F/AZD0120) targeting both BCMA and CD19 as a first-line treatment for newly diagnosed multiple myeloma (NDMM)."
Elva Chen
Dec 22, 20254 min read


"King of Blood Cancers" Hard to Treat and Prone to Relapse? Zhejiang Second Hospital's Self-Developed Upgraded CAR-NK Cell Therapy Strikes Back!
Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;
Elva Chen
Dec 18, 20255 min read


Unveiling Multiple Myeloma: From "The Great Mimicker" to a Controllable Chronic Disease
Multiple Myeloma (MM) is the second most common hematological malignancy worldwide and the third most common in China. It originates from plasma cells in the bone marrow, which are "immune warriors" that normally synthesize antibodies to fight infection. When these cells become malignant, they proliferate uncontrollably, crowding out healthy cells and destroying bone and kidney functions. Due to its insidious onset and diverse symptoms, the misdiagnosis rate is as high as 50%
Elva Chen
Dec 17, 20252 min read
bottom of page